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ABSTRACT
Introduction Most individuals treated for heroin use 
disorder receive opioid agonist treatment (OAT)(methadone 
or buprenorphine). However, OAT is associated with high 
attrition and persistent, occasional heroin use. There 
is some evidence for the effectiveness of contingency 
management (CM), a behavioural intervention involving 
modest financial incentives, in encouraging drug 
abstinence when applied adjunctively with OAT. UK drug 
services have a minimal track record of applying CM 
and limited resources to implement it. We assessed 
a CM intervention pragmatically adapted for ease of 
implementation in UK drug services to promote heroin 
abstinence among individuals receiving OAT.
Design Cluster randomised controlled trial.
Setting and participants 552 adults with heroin use 
disorder (target 660) enrolled from 34 clusters (drug 
treatment clinics) in England between November 2012 and 
October 2015.
Interventions Clusters were randomly allocated 1:1:1 to 
OAT plus 12× weekly appointments with: (1) CM targeted 
at opiate abstinence at appointments (CM Abstinence); 
(2) CM targeted at on- time attendance at appointments 
(CM Attendance); or (3) no CM (treatment as usual; TAU). 
Modifications included monitoring behaviour weekly and 
fixed incentives schedule.
Measurements Primary outcome: heroin abstinence 
measured by heroin- free urines (weeks 9–12). 
Secondary outcomes: heroin abstinence 12 weeks after 
discontinuation of CM (weeks 21–24); attendance; self- 
reported drug use, physical and mental health.
Results CM Attendance was superior to TAU in 
encouraging heroin abstinence. Odds of a heroin- negative 
urine in weeks 9–12 was statistically significantly greater 
in CM Attendance compared with TAU (OR=2.1; 95% CI 1.1 
to 3.9; p=0.030). CM Abstinence was not superior to TAU 
(OR=1.6; 95% CI 0.9 to 3.0; p=0.146) or CM Attendance 
(OR=1.3; 95% CI 0.7 to 2.4; p=0.438) (not statistically 
significant differences). Reductions in heroin use were not 
sustained at 21–24 weeks. No differences between groups 
in self- reported heroin use.
Strengths and limitations of this study
 ► To our knowledge, this is the first clinical trial to 
examine the effectiveness of contingency manage-
ment (CM) in promoting heroin abstinence among 
those in opioid agonist treatment in the UK.
 ► This study is a large cluster randomised trial con-
ducted at 34 drug treatment services in England.
 ► CM, as developed in the USA, was pragmatically 
adapted for ease of implementation in resource- 
poor UK substance use treatment settings.
 ► Adaptions included using drug service staff to deliv-
er all aspects of the CM intervention (as opposed to 
CM specialists); staff were trained, supported by a 
CM Handbook and regular supervision.
 ► Illicit drug use was monitored through urine drug 
screens once a week rather than more frequently 
using a fixed rather than escalating schedule.
2 Metrebian N, et al. BMJ Open 2021;11:e046371. doi:10.1136/bmjopen-2020-046371
Open access 
Conclusions A pragmatically adapted CM intervention for routine use 
in UK drug services was moderately effective in encouraging heroin 
abstinence compared with no CM only when targeted at attendance. CM 
targeted at abstinence was not effective.
Trial registration number ISRCTN 01591254.
INTRODUCTION
Opioid agonist treatment (OAT) (methadone and 
buprenorphine) is recognised globally as a clini-
cally1 2 and cost- effective2 3 treatment for opiate use 
disorder. However, its effectiveness is often undermined 
by high attrition associated with relapse into illicit drug 
use.4 In the UK, the National Institute for Health and 
Care Excellence recommends psychological therapies 
(including contingency management (CM)) be offered 
alongside OAT2 to support behaviour change.
CM is a behavioural intervention based on the princi-
ples of operant conditioning,5 delivered as a time- limited 
adjunct to existing evidence- based treatments (such as 
OAT) to amplify patient benefit. It involves providing 
positive reinforcement (usually monetary vouchers or 
prizes) contingent on achieving prespecified behaviour 
consistent with treatment goals.6 7
Evidence, primarily from US trials, shows that CM is an 
effective adjunct to substance use treatment in encouraging 
abstinence from drug use, including in treating drug use 
regardless of treatment setting, and for treating drug use 
(including cocaine, opiates and cocaine and polysubstance 
use) in opiate addiction treatment.8–12 However, there is 
weaker evidence for the effectiveness of CM in encour-
aging abstinence from illicit opiates among those receiving 
OAT.9 12–14
UK guidance, based on the evidence at the time,8 9 recom-
mended CM should be used in UK drug treatment to target 
the reduction of illicit drug use and encourage attendance at 
appointments.2 15 However, UK drug treatment services had 
little experience of applying CM, reduced treatment budgets 
and limited staff capacity; conditions likely to impede 
implementation of CM.6 We aimed to assess a CM inter-
vention pragmatically adapted for ease of implementation 
in routine UK practice. We have previously demonstrated 
that low- cost CM can affect short- term behaviour change of 
improved adherence to a hepatitis B vaccination schedule16 
achieving clear long- term health economic benefit.17 The 
trial reported here focused on more complex and longer 
term behaviour change. Specifically, we assessed the effec-
tiveness of two different 12- week CM schedules targeting 
(1) opiate abstinence or (2) attendance at clinical appoint-
ments, providing immediate positive reinforcement through 
vouchers delivered by trained staff, in achieving heroin absti-
nence among individuals receiving OAT in community drug 
treatment settings.
METHODS
Study design and setting
We employed a pragmatic cluster randomised controlled 
trial design described elsewhere.18 The unit of 
randomisation was the drug clinic (cluster) rather than 
individual participant. This was for three reasons: (1) to 
reduce the likelihood of contamination if staff were deliv-
ering and patients receiving different interventions at 
the same drug clinic; (2) to reduce interpatient contam-
ination as patients themselves constitute a local social 
network; and (3) to reduce the risk of low recruitment, 
poor compliance and high dropout within treatment 
as usual (TAU) arm if participants receiving TAU were 
denied an incentive offered to others in the same clinic. 
Sites were recruited in stages and then randomised. 
Thirty- four drug treatment clinics (clusters) in England 
(National Health Service (NHS): London, Birmingham, 
Sussex, Essex, Bath and Bristol, Dudley and Walsall; non- 
NHS: London, Hertfordshire and Birmingham) were 
randomly allocated to one of three conditions (described 
below) and tasked with recruiting a cluster sample of 22 
participants. Clinics were eligible if they provided OAT 
(methadone or buprenorphine), weekly clinical appoint-
ments and received enough OAT referrals to meet recruit-
ment targets.
Within each cluster, participants received the same allo-
cated condition, thus minimising the risk of contamina-
tion between intervention and control arms.
The trial tested the following research hypotheses:
 ► CM (positive reinforcement targeted at treatment 
attendance) will increase abstinence from street 
heroin when compared with TAU in which no positive 
reinforcement is offered.
 ► CM (positive reinforcement targeted at the provision 
of opiate- negative urine samples at treatment appoint-
ments) will increase abstinence from street heroin 
when compared with TAU in which no positive rein-
forcement is offered.
 ► Differences in the type of CM schedules will be associ-
ated with differences in heroin abstinence.
Having both CM interventions allowed us to assess 
whether any benefit (abstinence) derives from a direct 
effect of CM on abstinence as the behavioural target, or is 
a general benefit resulting from CM- stimulated improved 
attendance at clinical appointments (and possibly conse-
quent improvements in treatment retention).
Findings from parallel economic and process evalua-
tions are to be reported separately.
Participants
Eligible patients were aged 18 and above; seeking a new 
episode of OAT; regular users of street heroin (ie, self- 
reported use 15/preceding 30 days (at least 3 days/
week), and all (minimum 1) urine drug screens (UDS) 
in previous month positive for opiates); meeting Inter-
national Classification of Diseases 10th Revision criteria 
for opiate dependence; willing to receive 12- week CM 
intervention; at liberty to participate in the study for 24 
weeks; and willing and able to provide informed consent. 
We excluded patients if they could not read English 
and required an interpreter to understand a brief oral 
description of the study to ensure they would be able to 
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understand the CM intervention provided; were preg-
nant or breast feeding (due to being seen as a special 
population receiving special treatment provision); and/
or were referred through the criminal justice pathway 
and were receiving a community sentence on condition 
of attending drug treatment as they would be subject to 
additional contingencies which might influence their 
behaviour.
Randomisation and masking
Each cluster (drug clinic) was randomly assigned to OAT 
plus 12× weekly clinical appointments with either (1) CM 
Abstinence: positive reinforcement contingent on opiate 
abstinence monitored through UDS undertaken at each 
weekly appointment; (2) CM Attendance: positive rein-
forcement contingent on attendance on time; or (3) no 
CM (TAU; control condition).
Randomisation was undertaken independently by the 
King’s Clinical Trials Unit. Clusters were assigned to 
treatments using random permuted blocks within type 
of service provider strata (NHS or non- NHS) using a 
block length of 3 in a 1:1:1 allocation ratio. Laboratory 
personnel who completed the urinalysis and the statisti-
cian analysing primary outcome data were all blinded to 
treatment allocation.
Interventions
OAT was delivered in line with existing service protocols 
at all clinics and included weekly clinical appointments 
between 15 and 50 min with a named drug worker. 
Attending the service to obtain a prescription did not 
constitute attendance. The CM interventions (described 
below) were delivered adjunctively.
In our trial, CM, as developed in the USA, was pragmati-
cally adapted for use in resource- poor UK drug treatment 
services to ease future implementation. Key CM princi-
ples were retained; targeting a clearly defined behaviour, 
regular monitoring of that behaviour and providing an 
immediate reinforcer ensured that a clear contingent 
relationship was made between the positive behaviour 
and the reinforcer. The reinforcer was withheld if the 
target behaviour was not achieved. Adaptions included: 
(A) training drug workers to deliver CM (as opposed to 
CM specialists); (B) monitoring illicit drug use through 
weekly UDS (rather than more frequently) to fit routine 
UK practice of taking UDS once a week at the start of 
treatment and less frequently thereafter; and (C) using a 
fixed rather than escalating schedule, as drug service staff 
had previously reported the use of escalating schedules 
to be too difficult.19 CM consisted of positive reinforce-
ment—verbal praise and fixed value of £10 supermarket 
voucher at each appointment. Reasoning that anything 
lower would be unlikely to encourage participants to 
attend while escalation of the value would increase the 
costs of the intervention beyond most services budget.
‘CM Abstinence’: Reinforcement was conditional on 
attendance at weekly appointments and (A) during weeks 
1–4 (priming weeks) providing a UDS whatever the result 
and (B) during weeks 5–12 providing an opiate- negative 
UDS. UDS were undertaken using a drug integrated cup 
test to detect opioids. This test is able to detect opioids 
up to 1–3 days after use. While unable to confirm opioid 
abstinence over the week period, the test nevertheless 
provided clinically significant evidence of the partic-
ipants’ ability to abstain from using opioids over this 
briefer period. Instant UDS tests were completed at the 
start of each appointment. Staff provided the reinforcer 
immediately the target behaviour was achieved. Priming 
ensured participants gained experience of the reinforcer, 
while also addressing practitioner concerns about the 
difficulty in achieving abstinence during contempora-
neous titration up to a stable dose.
‘CM Attendance’: Eligibility to receive the reinforce-
ment was conditional solely on on- time attendance at the 
appointment (within 15 min of the scheduled appoint-
ment time).
Control: Participants received TAU (OAT plus 12× 
weekly appointments) with no CM.
The CM interventions ceased after week 12, at which 
point the frequency of appointments reverted to usual 
care for each service (ie, varied depending on drug 
service and patient needs).
Training and supervision
All staff providing clinical appointments received training 
on trial procedures. At CM sites, staff received bespoke 
1- day training on the principles and practice of CM 
(including simulation, role- play). Training was supported 
by a CM Handbook designed for UK services but which 
drew on international evidence and practice models.20
CM was delivered in the first 5–10 min of the appoint-
ment and audio recorded. A CM adherence measure 
was developed from measures available at the time21 but 
adapted to assess key CM competencies in UK service 
settings. Audio recordings were used to rate the scale 
which comprised 10 four- point Likert scale items. Adher-
ence was scored as poor (<33%), adequate (33%–66%) 
or good (>66%). The scale achieved good inter- rater reli-
ability (k=0.63; p<0.001).
Evidence suggests training alone is unlikely to change 
health professional behaviour unless supported by 
effective supervision.22 Group supervision sessions were 
provided to staff at intervention sites throughout the 
trial. The drug service psychologist/senior practitioner 
provided local supervision after receiving training in 
CM supervision. Audio recordings of CM delivery were 
available to local supervisors to provide feedback to staff. 
In turn, research team psychologists used recordings of 
supervision sessions to support their supervision of local 
supervisors.
Research assessments
Consenting participants completed a research interview 
(and were reimbursed £20 for time and travel) before 
enrolment into the trial and again at 12 and 24 weeks 
after enrolment. All participants were asked to provide 
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(research) UDS weekly between weeks 9–12 and 21–24. 
Weekly ‘urine collection clinics’ were established by the 
research team at each clinic (participants were reim-
bursed for travel) to enable participants to provide UDS 
outside of appointments. Participants’ attendance at 
appointments, receipt of CM vouchers and provision of 
urines for CM and research purposes were recorded.
Outcomes
The primary outcome measure of heroin abstinence 
was a once- weekly binary positive/negative heroin UDS 
collected at weeks 9–12 for laboratory drug testing.
Secondary outcome measures included retention in 
treatment, self- reported illicit drug use in the last 30 
days,23 alcohol use (Alcohol Use Disorders Identifica-
tion Test (AUDIT)),24 social functioning (Opiate Treat-
ment Index (OTI)),25 physical and mental health status 
(Short Form-36 (SF-36))26 and depression and anxiety 
(Hospital Anxiety and Depression Scale),27 obtained by 
researchers in face- to- face interviews with patients at base-
line, and 12 and 24 weeks. Confidential patient ratings of 
therapeutic alliance with their health professional were 
recorded at 4, 8 and 12 weeks after enrolment (Agnew 
Relationship Measure-5).28 A single- item measure of delay 
discounting29 and a motivation measure for drug absti-
nence30 were ancillary outcome measures and reported 
elsewhere.
The Adult Service Use Schedule adapted for drug 
users,31 health- related quality of life (EuroQoL 
5- Dimension 3- Level)32 and the WHO Health and Work 
Performance Questionnaire33 were measured for health 
economic analysis. Findings from the health economic 
analysis and parallel process evaluation are to be reported 
separately.
Sample size calculation
More detail is provided in the protocol.18 Lussier et al8 
estimated a mean weighted effect size of 0.39 from three 
studies with an opiate use outcome measure (CM vs 
control). For a two- sided test, alpha=0.05, 5% attrition, 
80% power to detect an effect size of 0.39, 111 partici-
pants per group were required. Accounting for clustering 
by clinic, this was inflated to 220 participants per arm 
(assuming an intraclass correlation of 0.05, 20 partici-
pants per cluster and 11 clusters per intervention leading 
to a design effect of 1.95). Clinics were initially advised to 
recruit >20 participants each (33×20=660 in total). After 
recruiting 13 clusters, with an attrition rate of 10%, larger 
than the expected 5%, clusters still recruiting were asked 
to increase recruitment from 20 to 22 participants.
Statistical analysis
Statistical analysis was carried out using Stata V.14/15 
according to the intention- to- treat principle. Variables 
were summarised using mean/SD, median/quartiles or 
frequencies/proportions as appropriate.
Refusal and non- attendance UDS were coded as posi-
tive (positive assumption) but results missing for other 
reasons (eg, discharged from treatment, in hospital or in 
prison) were initially left missing. This positive assump-
tion is commonly used in clinical practice and in studies 
of CM and was used in our previous trial.34
These responses were the dependent variables in a 
mixed effects logistic regression model (9–12 and 21–24 
weeks in separate models), with trial arm, the clinic type 
stratification factor and week dummy variables as fixed 
effects, and random intercepts for participants nested 
within clinic. Results are presented both from fitting a 
model fitted to data where (1) the positive assumption 
has been applied, but no further imputation has taken 
place, (2) further missing data were imputed (100 data 
sets) and estimates obtained using Rubin’s rules. The 
imputation model included clinic, trial arm, NHS strat-
ification factor, gender, heroin use at 12 and 24 weeks, 
and baseline measures including frequency of heroin use, 
AUDIT score, OTI social functioning score anxiety and 
depression, SF-36 physical and mental component scores 
and delay discounting, in addition to the four binary 
weekly urine sample measures. Moderation by type of 
opioid replacement (methadone or buprenorphine), 
NHS clinic versus non- NHS and the Charlson Index of 
multiple drug use was tested using the non- imputed data 
by adding treatment by moderator interaction terms each 
separately to the model described.
Differences in secondary continuous outcomes between 
the groups were estimated using linear mixed effects 
models with the 12 and 24- week outcomes as dependent 
variables, the same fixed and random effects as for the 
primary outcome, plus time point, treatment by time 
interaction and baseline values of the outcome where 
applicable as predictors. For the self- report binary drug 
use variables, marginal logistic generalised estimating 
equation (GEE) regression models were fitted (to esti-
mate marginal instead of potentially inflated conditional 
effects from mixed models, which were also fitted to 
compare),35 with the same variables as the linear mixed 
models and with clinic as a clustering variable. Missing 
data were not imputed.
Retention in the 12- week treatment programme was 
coded as weeks attended up to the point of continuous 
future non- attendance. Retention was compared between 
the groups using: (1) Fisher’s exact test for retention in 
the trial overall, (2) a logistic GEE model for binary reten-
tion in opioid treatment at 12 weeks (with exchangeable 
correlation structure and 1000 repetition bootstrap SEs), 
and (3) Kaplan- Meier and Cox regression analyses for 
time until continuous treatment non- attendance, with 
trial group and NHS stratification factor as predictors and 
clinic as a clustering variable.
Patient and public involvement
A Service User Research Advisory Group (SURAG) was 
established before the trial commenced, comprising 14 
service users with direct experience of receiving OAT. 
The group met once every 6 months to provide advice on 
the design, conduct and progress of the research. The 
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SURAG helped significantly to make the trial procedures 
acceptable and aided implementation.
RESULTS
Sample
Between September 2012 and September 2015, we 
randomly allocated 34 clinics (clusters) (of 61 consid-
ered) to three treatments (figure 1; and see online supple-
mental material). Of the 34 clinics, all provided OAT, the 
majority were NHS (62%) and just under one- half were 
within London (47%). Figure 1 shows that across 34 clus-
ters, 789 patients were screened for eligibility, of whom 
552 (31.8%) were consented and enrolled (between 
November 2012 and October 2015), a figure that fell short 
of our target of 660. One cluster did not recruit any partic-
ipants. Although we recruited the target number of sites, 
we were unable to recruit 20 (and latterly 22) participants 
at all sites. Recruiting sites and participants at each site 
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. CM, contingency management; TAU, treatment as 
usual.
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were challenging due to retendering of service contracts 
which affected many sites during the trial period. Two 
services were decommissioned during the trial.
Retention in the trial was high and comparable across 
trial arms. Eight participants actively withdrew from the 
trial (CM Abstinence=4 (2%); CM Attendance=1 (1%); 
TAU=3 (2%), p=0.50).
Characteristics
Study participants were broadly representative of patients 
entering OAT in England (table 1). They were mostly 
male (404; 73%), white (435; 79%) and with a mean age 
of 38.2 years (SD 8.8). They had first used opiates at the 
mean age of 23 years (SD 8), first injected at a mean age 
of 26 years (SD 8) and first received treatment at a mean 
age of 30 years (SD 8). They had previously been in opiate 
treatment a median of two times (25th, 75th percentiles 
1 to 4). Over half had been in prison (291; 53%). Fifty- 
seven per cent were prescribed methadone (315), 43% 
buprenorphine (237).
All participants (552) self- reported using heroin in the 
month prior to interview (including two reporting using 
non- prescribed pharmaceutical heroin). Three- quarters 
reported using crack (419; 76%) while 23% used benzo-
diazepines (n=129). Half drank alcohol (53%; n=310) 
and nearly all used tobacco (531; 96%) (table 2; and see 
online supplemental material).
There was reasonable balance across the three trial 
arms in terms of baseline sociodemographic, drug use, 
health and treatment experience variables. However, 
there were more women in the CM Attendance group, 
fewer white individuals in the CM Abstinence group and 
a smaller proportion with insecure housing status in the 
CM Attendance group.
Abstinence from heroin at 12 weeks
Of the 2208 scheduled UDS (552 participants × 4 urines 
for weeks 9–12), 601 (27%) were not obtained due to 
non- compliance (refusal or DNA) and were imputed as 
positive (positive assumption), with the greatest number 
of these being in the TAU group. Additionally, 454 
(21%) were treated as missing, including: 260 (12%) not 
obtained due to unable to contact, 77 (3%) not obtained 
due to clinic error, 15 (1%) unable to provide a sample, 
55 (3%) in prison (47) and in hospital (8), and for 10 
(0.5%) the reason was missing. The percentage of UDS 
results missing by week and trial arm are shown in table 3.
Results from the analyses with and without imputation 
were similar (table 4), so results from imputed data are 
discussed. Participants in the CM Attendance group had 
statistically significantly greater odds of a heroin- negative 
urine at 9–12 weeks compared with those in the TAU 
group (OR=2.1; 95% CI 1.1 to 3.9; p=0.030). There were 
no statistically significant differences between the CM 
Abstinence and TAU group (OR=1.6; 95% CI 0.9 to 3.0; 
p=0.146) or CM Attendance group (OR=1.3; 95% CI 0.7 
to 2.4; p=0.438).
Figure 2 shows the observed (dashed line) and model- 
predicted (solid line) expected probabilities of a heroin- 
negative urine over the 4 weeks of the primary outcome 
period. Based on estimated proportions from model 
1 in table 4, a higher proportion of those in CM Atten-
dance (62%) or CM Abstinence (57%) provided a nega-
tive heroin urine sample at week 12 compared with TAU 
(48%). The intraclass correlations from the non- imputed 
data were 0.03 (95% CI 0.01 to 0.11) at the clinic level.
There was no moderation of trial intervention 
outcome by medication or treatment setting (buprenor-
phine vs methadone (χ2(2)=1.89; p=0.389); NHS or 
non- NHS service (χ2(2)=4.96; p=0.084)) or by other or 
multiple drug use (Charlson Index of multiple drug use 
(χ2(2)=4.93; p=0.085)).
Abstinence from heroin at 24 weeks
There were no statistically significant differences among 
groups in heroin abstinence for weeks 21–24 (table 4).
Figure 3 shows the observed (dashed line) and model 
1 expected probabilities (solid line) of a heroin- negative 
UDS over the 4 weeks of the follow- up period (weeks 
21–24). The estimated proportions of those providing a 
negative heroin UDS at 24 weeks from model 1 in figure 3 
were similar across groups: CM Abstinence (44%); CM 
Attendance (45%); TAU (37%).
Attendance
Figure 4 shows that 60% of those receiving CM Abstinence 
and 59% receiving CM Attendance attended their first 
appointment on time, compared with 46% of the TAU 
group. Eleven per cent of participants did not attend any 
weekly appointments (CM Abstinence=11%; CM Atten-
dance=7%; TAU=14%).
Attrition at each week was highest in the TAU group, 
with the proportion of participants attending appoint-
ments falling from 46% to 24% between weeks 1 and 
12. In the CM Abstinence group, there was a decline in 
attendance from 53% (week 4) down to 45% (week 5) 
with a steady decline thereafter to 33% attending at week 
12. Attendance in the CM Attendance group remained 
consistent with a slight decline from 59% (week 1) to 51% 
(week 12). Most attendance was on time (within 15 min) 
(figure 4).
Retention in 12 weekly appointments
The proportions attending all of the 12- week appoint-
ments differed across the groups, with a higher propor-
tion attending in CM Attendance as compared with CM 
Abstinence and TAU groups (56% vs 39% and 30%). 
Participants in the CM Attendance group had statistically 
significantly greater odds of full attendance compared 
with those in TAU (OR=3.1; 95% CI 2.0 to 4.6; p<0.001). 
There were no statistically significant differences between 
CM Abstinence and TAU (OR=1.5; 95% CI 0.9 to 2.4; 
p=0.099).
Participants in the CM Attendance group attended 
longer than those in the CM Abstinence group or TAU 
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group. Participants in the CM Abstinence group had 
statistically significantly greater risk of dropping out of 
the appointments before week 12 compared with those 
in TAU group (HR=1.9; 95% CI 1.5 to 2.5; p<0.001) and 
in CM Attendance group (HR=1.7; 95% CI 1.2 to 2.3; 
p=0.002) (figure 5).
Clinical outcomes: self-reported drug use
Self- reported heroin use reduced in all groups from 
nearly 100% (99.6%; 550) to 74% (291) at week 12, while 
the median number of days used reduced from 28 (21, 
30) to 4 (0, 15). Self- reported use of crack and benzodiaz-
epines reduced in the trial population from 76% to 54% 
and 23% to 16%, respectively, at 12 weeks. Self- reported 
alcohol and tobacco use remained similar (from 56% to 
61% and 96% to 95%, respectively). There were no signif-
icant differences in these outcomes between groups at 
12 weeks (tables 2 and 5; and see online supplemental 
material).
At 24- week follow- up, we found no difference in self- 
reported illicit drug use between groups. However, 







Summary statistics for binary Yes/
No to ‘use in the past 30 days’? 
(Missing shown but n (%) proportions 
calculated disregarding missing)
n (%) n (%) n (%) n (%)
  Baseline
  Used heroin in the last 30 days 205 (100) 173 (99) 172 (99) 550 (99.6)
  Did not use heroin in the last 30 
days
0 (0) 1 (1) 1 (1) 2 (0.4)
  Missing 0 0 0 0
  12 weeks
  Used heroin in the last 30 days 96 (73) 111 (78) 84 (72) 291 (74)
  Did not use heroin in the last 30 
days
36 (27) 32 (22) 32 (28) 100 (26)
  Missing 73 31 57 161
  24 weeks
  Used heroin in the last 30 days 97 (79) 85 (78) 66 (75) 248 (78)
  Did not use heroin in the last 30 
days
26 (21) 24 (22) 22 (25) 72 (23)
  Missing 82 65 85 232
Number of days taking heroin in the last 30 days
  Baseline
  n 204 173 173 550
  Number missing 1 1 0 2
  Proportion missing 0.49 0.57 0 0.36
  Median (25th, 75th percentiles) 28.00 (22.00, 30.00) 27.00 (21.00, 30.00) 28.00 (21.00, 30.00) 28.00 (21.00, 30.00)
  12 weeks
  n 132 143 116 391
  Number missing 73 31 57 161
  Proportion missing 35.61 17.82 32.95 29.17
  Median (25th, 75th percentiles) 4.00 (0.00, 15.00) 5.00 (1.00, 13.00) 4.00 (0.00, 15.00) 4.00 (0.00, 15.00)
  24 weeks
  n 123 108 88 319
  Number missing 82 66 85 233
  Proportion missing 40.00 37.93 49.13 42.21
  Median (25th, 75th percentiles) 5.00 (1.00, 15.00) 4.50 (1.00, 15.00) 3.50 (0.50, 20.00) 4.00 (1.00, 15.00)
CM, contingency management; TAU, treatment as usual.
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there was weak evidence of increased odds of alcohol 
use in the last 30 days in CM Attendance as compared 
with CM Abstinence (OR=1.9; 95% CI 1.0 to 3.5; 
p=0.048), and evidence of fewer days using tobacco in 
the last 30 days in TAU as compared with CM Absti-
nence (OR=2.1; 95% CI −0.3 to −3.9; p=0.024) (see 
online supplemental material). Mixed effects models 
gave similar results.
Table 4 Primary outcome analysis: odds of subjects providing a heroin- negative urine over weeks 9–12 and 21–24
Contrast OR 95% CI P value
Weeks 9–12
(1) Outcome: repeated binary heroin result with refused and 
DNA=positive sample
(n=483, no multiple imputation)
CM Abstinence versus 
TAU
1.67 0.89 to 3.14 0.114
CM Attendance versus 
TAU*
2.19 1.15 to 4.15 0.017
CM Attendance versus 
CM Abstinence
1.31 0.71 to 2.44 0.391
(2) Outcome: repeated binary heroin result with refused and 
DNA=positive sample (ie, analysis 1) and remaining missing 
multiply imputed
(n=552, using multiple imputation)
CM Abstinence versus 
TAU
1.59 0.85 to 3.01 0.146
CM Attendance versus 
TAU*
2.05 1.07 to 3.91 0.030
CM Attendance versus 
CM Abstinence
1.29 0.68 to 2.41 0.438
Weeks 21–24
(1) Repeated binary analysis for weeks 21–24 with refused and 
DNA=0
(n=409, no multiple imputation)
CM Abstinence versus 
TAU
1.71 0.72 to 4.09 0.225
CM Attendance versus 
TAU
1.66 0.69 to 4.00 0.261
CM Attendance versus 
CM Abstinence
0.97 0.41 to 2.28 0.939
(2) Analysis 1 with remaining missing multiply imputed
(n=552, using multiple imputation)
CM Abstinence versus 
TAU
1.46 0.66 to 3.26 0.352
CM Attendance versus 
TAU
1.29 0.57 to 2.92 0.543
CM Attendance versus 
CM Abstinence
0.89 0.40 to 1.93 0.751
*Significant at 0.05.
CM, contingency management; TAU, treatment as usual.
Figure 2 Probability of heroin- negative urine applying 
positive assumption over weeks 9–12. CM, contingency 
management; TAU, treatment as usual.
Figure 3 Probability of heroin- negative urine applying 
positive assumption over weeks 21–24. CM, contingency 
management; TAU, treatment as usual.
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Clinical outcomes: health and social
There were no differences between the groups in clinical 
outcomes at week 12 or 24 (for statistical tests see online 
supplemental material). A similar therapeutic alliance 
score was reported by all groups at 4, 8 and 12 weeks (see 
online supplemental material).
Adherence to CM
Both CM Abstinence and CM Attendance achieved a 
score of ‘adequate’ adherence to the CM manual. It is 
important to note these averages were on the lower 
end of the range of scores in this category (CM Absti-
nence=38.33%, SD=9.49 (range 24.6%–56.3%); CM 
Attendance=44.15%, SD=17.07 (range 16.7%–68.2%)).
Serious adverse events
There were 25 serious adverse events in 22 participants: 
CM Abstinence=10 in 9 participants; CM Attendance=8 
in 7 participants; TAU=7 in 6 participants. The number 
of deaths was 3 (CM Abstinence=1; CM Attendance=2). 
None were related to the trial intervention.
DISCUSSION
We found the adapted CM intervention targeted at atten-
dance was moderately effective in encouraging heroin 
abstinence compared with TAU. CM Abstinence was not 
more effective than TAU or CM Attendance.
The UK’s clinical guidance,2 15 which promotes the use 
of CM, was influenced by systematic reviews and meta- 
analysis conducted at least 10 years ago which showed 
CM was effective in encouraging abstinence from a 
range of drugs.9 Previous reviews examining the effective-
ness of CM in promoting opioid abstinence have been 
mixed9–12 14 with the most recent systematic review and 
meta- analysis concluding there was no evidence of CM 
working better than control in encouraging abstinence 
from non- prescribed opiates during OAT.14 Our find-
ings concur with the most recent meta- analysis; although 
adapting CM for ease of implementation in resource- 
poor settings may have caused it to lose some of its poten-
tial effectiveness.
When our adapted CM intervention was targeted at 
attendance only, it was superior to TAU in encouraging 
heroin abstinence. It has been argued that clinical benefit 
arises from regular attendance at clinical appointments 
and overall retention in treatment.36 Our findings suggest 
CM can improve attendance (when targeted at it) among 
populations who often prove challenging to engage with 
and retain in treatment and that the clinical benefit we 
observed supports such arguments.
The CM interventions we evaluated retained the main 
principles of CM, but modifications were made to ensure 
ease of implementation in UK settings with limited treat-
ment budgets.
First, in the UK, resources are limited. Patients 
receiving OAT attend their service and receive UDS once 
a week at the start of treatment and less frequently there-
after. Previous studies exploring views of CM among UK 
drug treatment staff and patients found that staff viewed 
the US frequency of urine testing to be too resource 
heavy for the UK settings and service users felt strongly 
that such a regime would act as a disincentive.37 Hence, 
opiate abstinence was monitored through once- weekly 
UDS rather than multiple tests per week. Opioids can 
only be detected up to 1–3 days after use so the UDS 
cannot confirm opioid abstinence over the week period, 
only provide evidence of abstinence over this briefer 
period, potentially reducing the impact of the reinforcer. 
As CM Abstinence had no effect on either UDS or self- 
reported heroin use, it is possible that CM Abstinence 
only encouraged abstinence in the 1–3 days before an 
appointment and a UDS test. While it may be argued that 
such behaviour change can be clinically significant to the 
individual patient, the absence of change in secondary 
outcomes suggests we should be cautious about inferring 
any significant clinical benefit.
Second, while the CM evidence base demonstrates the 
efficacy of escalating value incentives,8–13 we used a fixed- 
value incentive. In a previous UK study of CM targeted 
at hepatitis B vaccination, undertaken by the authors, we 
Figure 4 Attendance at appointments. CM, contingency 
management; TAU, treatment as usual.
Figure 5 Time to continuous appointment non- attendance. 
CM, contingency management; TAU, treatment as usual.
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found escalating schedule was more difficult to imple-
ment and for staff to adhere to.16 Employing escalating 
schedules might have risked unacceptable levels of 
protocol violations while also increasing the costs of the 
intervention, and limiting potential for translation into 
routine clinical practice. We used £10 vouchers—a figure 
our SURAG regarded as sufficient to encourage partici-
pants to attend and provide a UDS.
Third, it was critical that the CM schedule was accept-
able to participants and supported by staff. Our SURAG 
argued that having to provide opiate- negative UDS would 
be challenging during titration and staff felt monitoring 
at this point may be undermining. In response, we 
introduced an initial 4- week priming phase in the CM 
Abstinence arm, during which participants received rein-
forcement for on- time provision of a UDS, irrespective of 
the result. The use of priming in CM ensures that patients 
experience receipt of the reinforcer early in treatment.6 
As participants were entering OAT and undergoing dose 
titration for their methadone/buprenorphine medica-
tion, priming provided an opportunity for participants 
to receive exposure to the incentive without the expecta-
tion that they needed to be heroin abstinent during this 
period.
Fourth, vouchers were chosen as reinforcers as there 
is good evidence for their effectiveness11 12 and costs 
were relatively low given the once- a- week frequency of 
reinforcement.
Adherence to CM as set out in the training manual 
was somewhat better in the CM Attendance group than 
CM Abstinence group but not significantly so. Movement 
of trained staff and supervisors away from participating 
services may well have impacted on adherence. Further 
exploration of the relationship between adherence and 
outcomes and the factors which may affect this (such as 
individual competence or service organisational factors) 
will help to clarify this.
Although CM has a strong evidence base in achieving 
behaviour change, there is weaker evidence for 
behaviours sustained once the incentives are removed. 
Previous studies have found differing results with only a 
small treatment effect following discontinuation of incen-
tives.11 In this study, the reduction in heroin use was not 
sustained after discontinuation of CM. We are unable to 
conclude whether this was due to the cessation of CM 
or weekly appointments. These appointments were not 
routine practice in most drug services after 12 weeks but 
considered good clinical practice in the first 12 weeks 
of treatment.38 Further research is needed to better 
understand how to maintain positive behaviour change, 
including whether the reinforcer needs to be maintained, 
given intermittently, or tapered. We also need to explore 
the impact of the cessation, or reduced frequency of 
appointments after 12 weeks.
While there is a growing body of evidence for CM, it 
has not been widely implemented in UK drug treat-
ment services. Similarly, the actual adoption and imple-
mentation of CM programmes in US community- based 
treatment programmes (including those where most 
research on CM has been undertaken) is rare,39 possibly 
due to limited staff capacity, resources and treatment 
budgets6 though there are some reports of successful 
implementation.40
Adapting CM for ease of implementation in resource- 
poor settings may have led to a loss of some of its potential 
effectiveness. Therefore, future research should consider 
how best to implement CM in routine practice both in 
UK and international contexts and should consider 
Table 5 ORs for Opiate Treatment Index (OTI) measures of heroin use in the last 30 days assessed at 12 and 24 weeks: use in 







Heroin use in the last 30 days Y/N across groups—GEE model results
  12- week CM Attendance versus CM Abstinence 1.28 0.77 2.14 0.336
  12- week TAU versus CM Abstinence 0.98 0.56 1.70 0.936
  12- week TAU versus CM Attendance 0.76 0.47 1.23 0.268
  24- week CM Attendance versus CM Abstinence 0.95 0.51 1.78 0.876
  24- week TAU versus CM Abstinence 0.80 0.40 1.63 0.545
  24- week TAU versus CM Attendance 0.85 0.42 1.69 0.633
Mean differences number of days used in the last 30 days across groups
  12- week CM Attendance versus CM Abstinence −0.42 −3.11 2.27 0.760
  12- week TAU versus CM Abstinence 0.02 −2.77 2.80 0.990
  12- week TAU versus CM Attendance 0.44 −2.33 3.21 0.757
  24- week CM Attendance versus CM Abstinence −0.25 −3.06 2.56 0.859
  24- week TAU versus CM Abstinence −0.13 −3.06 2.80 0.931
  24- week TAU versus CM Attendance 0.13 −2.85 3.10 0.934
CM, contingency management; GEE, generalised estimating equation; TAU, treatment as usual.
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different models of delivery (including the use of mobile 
telephone technology).
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